Get the Stockscreener App
2.29
8.03%
-0.20
After Hours:
2.34
0.05
+2.18%
Relay Therapeutics Inc stock is traded at $2.29, with a volume of 2.79M.
It is down -8.03% in the last 24 hours and down -28.44% over the past month.
See More
Previous Close:
$2.49
Open:
$2.33
24h Volume:
2.79M
Relative Volume:
1.23
Market Cap:
$388.21M
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-0.8179
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-23.41%
1M Performance:
-28.44%
6M Performance:
-64.71%
1Y Performance:
-67.93%
1-Day Range:
$2.26
$2.38
1-Week Range:
$2.26
$2.97
52-Week Range:
$2.26
$10.72
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
399 BINNEY STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
2.29 | 388.21M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Thrivent Financial for Lutherans Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Teacher Retirement System of Texas Purchases 5,492 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics stock hits 52-week low at $2.44 - Investing.com India
Relay Therapeutics stock hits 52-week low at $2.44 By Investing.com - Investing.com UK
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Virtu Financial LLC - Defense World
Relay Therapeutics’ SWOT analysis: promising drug data boosts stock outlook - Investing.com
Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! - Insider Monkey
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by HighTower Advisors LLC - Defense World
Charles Schwab Investment Management Inc. Decreases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $3.01 amid market challenges - Investing.com India
Bank of New York Mellon Corp Buys 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Investor Alert: What’s Really Going On At Relay Therapeutics Inc (NASDAQ: RLAY) - Stocks Register
Victory Capital Management Inc. Has $63,000 Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Steward Partners Investment Advisory LLC Purchases 4,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Head-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: promising drug faces stiff competition - Investing.com India
Arizona State Retirement System Acquires 7,547 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
HC Wainwright Reiterates “Buy” Rating for Relay Therapeutics (NASDAQ:RLAY) - Defense World
Rhumbline Advisers Acquires 13,532 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
New York State Common Retirement Fund Has $121,000 Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
The Goldman Sachs Group Lowers Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - Defense World
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low After Analyst Downgrade - Defense World
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP - TipRanks
Relay Therapeutics stock target cut to $12 at Citizens JMP - Investing.com
Buy Rating for Relay Therapeutics Driven by Strategic Advancements and Promising Clinical Trial Developments - TipRanks
RLAY stock touches 52-week low at $3.34 amid market challenges - Investing.com
Relay Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relay Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Relay Therapeutics reports Q4 EPS (45c), consensus (55c) - TipRanks
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics, Inc. SEC 10-K Report - TradingView
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnin - GuruFocus.com
What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings - Yahoo Finance
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - WICZ
Can These Two Major Healthcare Conferences Reveal Relay Therapeutics' Next Big Move? - StockTitan
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics (RLAY) Projected to Post Quarterly Earnings on Thursday - Defense World
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - The Manila Times
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):